Production (Stage)
Acumen Pharmaceuticals, Inc.
ABOS
$1.02
-$0.01-0.97%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 25.27M | 91.18M | 902.00K | 19.53M | 12.45M |
| Gross Profit | -25.27M | -91.18M | -902.00K | -19.53M | -12.45M |
| SG&A Expenses | 5.10M | 5.03M | 5.02M | 4.85M | 5.33M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 30.37M | 39.60M | 32.27M | 24.38M | 17.77M |
| Operating Income | -30.37M | -39.60M | -32.27M | -24.38M | -17.77M |
| Income Before Tax | -28.80M | -37.15M | -29.77M | -20.54M | -14.87M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -28.80M | -37.15M | -29.77M | -20.54M | -14.87M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -28.80M | -37.15M | -29.77M | -20.54M | -14.87M |
| EBIT | -30.37M | -39.60M | -32.27M | -24.38M | -17.77M |
| EBITDA | -30.36M | -39.58M | -32.25M | -24.36M | -17.76M |
| EPS Basic | -0.48 | -0.62 | -0.50 | -0.34 | -0.25 |
| Normalized Basic EPS | -0.30 | -0.39 | -0.31 | -0.21 | -0.16 |
| EPS Diluted | -0.48 | -0.62 | -0.50 | -0.34 | -0.25 |
| Normalized Diluted EPS | -0.30 | -0.39 | -0.31 | -0.21 | -0.16 |
| Average Basic Shares Outstanding | 60.53M | 60.08M | 60.08M | 60.08M | 59.81M |
| Average Diluted Shares Outstanding | 60.53M | 60.08M | 60.08M | 60.08M | 59.81M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |